Inebilizumab - Viela Bio

Next Previous
Drug Profile

Inebilizumab - Viela Bio

Alternative Names: 16C4-aFuc; A-fucosylated anti-CD19 antibody; Anti-CD19 MAb; MEDI 551

Latest Information Update: 24 Mar 2018

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Cellective Therapeutics
  • Developer MedImmune
  • Class Antineoplastics; Eye disorder therapies; Monoclonal antibodies; Skin disorder therapies
  • Mechanism of Action CD19 antigen inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Neuromyelitis optica
  • New Molecular Entity Yes

Highest Development Phases

  • Phase II/III Neuromyelitis optica
  • Phase II Chronic lymphocytic leukaemia
  • Phase I/II B cell lymphoma; Multiple sclerosis
  • No development reported Multiple myeloma; Systemic scleroderma
  • Discontinued Diffuse large B cell lymphoma

Most Recent Events

  • 04 Nov 2017 No recent reports of development identified for phase-0 development in Multiple-myeloma(Newly diagnosed) in USA (IV)
  • 04 Nov 2017 No recent reports of development identified for phase-I development in B-cell lymphoma in Italy (IV, Infusion)
  • 04 Nov 2017 No recent reports of development identified for phase-I development in B-cell lymphoma(Combination therapy, Second-line therapy or greater) in Belgium (IV, Infusion)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top